New combo therapy aims to keep leukemia away after transplant
NCT ID NCT07493408
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding asciminib to standard tyrosine kinase inhibitors can prevent relapse in patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia after a stem cell transplant. 45 participants will be randomly assigned to receive asciminib plus standard drugs or standard drugs alone. The study will monitor relapse rates and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Asciminib
- What this could lead to
- If it works, this could reduce the chance of leukemia returning after a stem cell transplant, offering a new maintenance option.
- What could go wrong
- This is a small, early-phase trial (45 participants) that hasn't started yet. The added drug may cause side effects or not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC TRANSFORMATION OF CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.